Manganism
Overview
Manganism, also known as manganese-induced parkinsonism, is a neurotoxic disorder caused by excessive exposure to manganese (Mn), a trace metal essential for normal cellular function but toxic in high concentrations[@aschner2007]. The disease is characterized by progressive movement abnormalities, predominantly parkinsonian features, along with psychiatric manifestations including mood changes, irritability, and cognitive impairment[@guilarte2006].
The condition was first described in 1837 by John Couper in a French manganese sulfate worker, making it one of the earliest documented occupational neurological diseases[@couper]. Manganism occurs primarily in workers exposed to high levels of manganese through mining, ore processing, steel production, welding, and battery manufacturing[@mergler1999]. The global burden of manganism is difficult to estimate due to underreporting and misdiagnosis as idiopathic [Parkinson's disease](/diseases/parkinsons-disease), but occupational studies suggest prevalence rates of 5-15% among heavily exposed workers[@racette2012].
Epidemiology
Occupational Exposure
...Manganism
Overview
Manganism, also known as manganese-induced parkinsonism, is a neurotoxic disorder caused by excessive exposure to manganese (Mn), a trace metal essential for normal cellular function but toxic in high concentrations[@aschner2007]. The disease is characterized by progressive movement abnormalities, predominantly parkinsonian features, along with psychiatric manifestations including mood changes, irritability, and cognitive impairment[@guilarte2006].
The condition was first described in 1837 by John Couper in a French manganese sulfate worker, making it one of the earliest documented occupational neurological diseases[@couper]. Manganism occurs primarily in workers exposed to high levels of manganese through mining, ore processing, steel production, welding, and battery manufacturing[@mergler1999]. The global burden of manganism is difficult to estimate due to underreporting and misdiagnosis as idiopathic [Parkinson's disease](/diseases/parkinsons-disease), but occupational studies suggest prevalence rates of 5-15% among heavily exposed workers[@racette2012].
Epidemiology
Occupational Exposure
Manganism predominantly affects workers in the following industries[@santamaria2007]:
- Mining and ore processing: Manganese mining and concentration
- Steel and metallurgy: Ferroalloy production, steel manufacturing
- Welding: Particularly gas metal arc welding and flux-cored arc welding
- Battery manufacturing: Production of alkaline and lithium-manganese batteries
- Glass and ceramics: Manganese as a coloring agent
- Chemical industry: Production of manganese compounds
Risk Factors
The development of manganism depends on[@lucchini2009]:
- Duration of exposure: Typically 1-20 years of occupational exposure
- Intensity of exposure: Air concentrations above 1 mg/m³ associated with increased risk
- Individual susceptibility: Genetic factors affecting manganese metabolism
- Pre-existing liver disease: Impaired manganese excretion increases vulnerability
- Nutritional status: Iron deficiency enhances manganese absorption
Demographics
- Age: Typically presents in middle-aged workers (40-60 years)
- Sex: Male predominance due to occupational distribution
- Geographic clusters: Reported in industrial regions worldwide
- Latency: Symptoms may develop months to years after exposure cessation[@jiang2007]
Toxicology
Manganese Chemistry
Manganese is a transition metal existing in multiple oxidation states (Mn²⁺ through Mn⁷⁺), with Mn²⁺ and Mn⁴⁺ being the most biologically relevant[@erikson2003]. The divalent form (Mn²⁺) crosses the blood-[brain](/brain-regions/overview) barrier through specific transporters and accumulates in the [brain](/brain-regions/overview)[@takeda2003].
Sources of Exposure
Occupational Sources
- Inhalation of manganese-containing dust and fumes
- Dermal contact with manganese compounds
- Ingestion from contaminated hands
Environmental Sources
- Contaminated groundwater near industrial sites
- Soy-based infant formula (historical episodes)
- Manganese in gasoline additives (former use of MMT)[@dobson2004]
Pharmacokinetics
- Absorption: Primarily through lungs (50-90% of inhaled manganese)
- Distribution: Liver, [brain](/brain-regions/overview), bone, and endocrine organs
- Metabolism: Binding to transferrin and various proteins
- Excretion: Primarily via bile into feces; half-life in [brain](/brain-regions/overview): 1-2 years[@roth2006]
Pathophysiology
Mechanisms of Neurotoxicity
Mitochondrial Dysfunction
Manganese accumulates in mitochondria due to its role as a calcium analog, leading to[@guilarte2010]:
- Impaired oxidative phosphorylation
- Increased reactive oxygen species (ROS) generation
- Disruption of mitochondrial membrane potential
- Activation of apoptotic pathways
Neuroinflammation
Manganese exposure triggers[@liu2006]:
- Microglial activation and proliferation
- Increased pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
- Oxidative stress from activated [microglia](/cell-types/microglia)
- Blood-[brain](/brain-regions/overview) barrier disruption
Glutamatergic Excitotoxicity
Manganese affects glutamatergic signaling through[@guilarte2008]:
- Altered glutamate transporter expression
- Increased NMDA receptor activity
- Calcium dysregulation
- GABAergic neuron dysfunction
Dopaminergic Dysfunction
The characteristic parkinsonian features result from[@kalf2007]:
- Selective accumulation in globus pallidus
- Loss of dopaminergic [neurons](/cell-types/neurons) in [substantia nigra](/brain-regions/substantia-nigra) pars compacta
- Decreased dopamine levels in striatum
- Impaired dopaminergic signaling
Neuropathology
Gross Pathology
- Globus pallidus: Most affected region, brownish discoloration
- Substantia nigra: Variable involvement, less severe than in [Parkinson's disease](/diseases/parkinsons-disease)
- Striatum: Caudate and putamen show variable changes
- Liver: May show cirrhosis or normal appearance[@olanow1996]
Histological Findings
- Neuronal loss: Selective vulnerability of GABAergic [neurons](/cell-types/neurons) in globus pallidus
- Astrocytosis: Proliferation of [astrocytes](/cell-types/astrocytes) in affected regions
- Manganese deposition: Visible as brown pigment in [neurons](/cell-types/neurons) and glia
- Spheroids: Axonal swellings in basal ganglia[@jellinger1999]
Neuroimaging Findings
- MRI T1 hyperintensity: Increased signal in globus pallidus on T1-weighted images
- PET studies: Reduced fluorodopa uptake in striatum
- SPECT imaging: Preserved dopamine transporter binding (distinguishes from Parkinson's)[@kim2011]
- Transcranial ultrasound: Increased echogenicity in [substantia nigra](/brain-regions/substantia-nigra)[@vlter2007]
Clinical Features
Movement Disorders
The core movement disorder in manganism includes[@criswell2011]:
Parkinsonism
- Bradykinesia: Slowness of voluntary movements
- Rigidity: Cogwheel type, predominant in lower extremities
- Resting tremor: Less prominent than in idiopathic [Parkinson's disease](/diseases/parkinsons-disease)
- Postural instability: Impaired balance and fall tendency
Dystonia
- Limb dystonia: Persistent muscle contractions causing abnormal postures
- Facial dystonia: Mask-like expression with reduced blink rate
- Foot dystonia: Inverted or everted feet during walking[@koller2004]
Gait Disturbance
- Festinating gait: Short, shuffling steps
- Waddling gait: Due to lower limb involvement
- Freezing episodes: Sudden inability to initiate movement[@tuschl2013]
Psychiatric Manifestations
- Mood changes: Depression, anxiety, irritability
- Psychosis: Hallucinations, delusions (less common)
- Cognitive impairment: Executive dysfunction, reduced attention
- Behavioral changes: Apathy, social withdrawal[@bowler2006]
Other Neurological Features
- Speech abnormalities: Slow, monotone speech
- Swallowing difficulties: Dysphagia due to orofacial involvement
- Olfactory dysfunction: Typically preserved (distinguishes from [Parkinson's disease](/diseases/parkinsons-disease))[@sato2015]
- Sleep disorders: REM sleep behavior disorder is rare
Systemic Features
- Liver involvement: May show abnormal liver function tests
- Hematological changes: Anemia in some cases
- Pulmonary symptoms: Cough, dyspnea from concurrent exposure[@wang1996]
Disease Course
Progressive Phase
- Symptoms develop during active exposure or shortly after
- Progress over months to years even after exposure cessation
- May plateau in some patients
Stable Phase
- Movement symptoms may stabilize after exposure ends
- Psychiatric features may continue to evolve
- Some improvement possible with chelation therapy[@kitamura2006]
Diagnosis
Diagnostic Criteria
The diagnosis is based on[@selikhova2008]:
Occupational history: Documented manganese exposure
Clinical features: Parkinsonism with predominant lower limb involvement
Neurological examination: Bradykinesia, rigidity, dystonia
Imaging findings: MRI T1 hyperintensity in globus pallidus
Exclusion of other causes: [Parkinson's disease](/diseases/parkinsons-disease), atypical parkinsonismClinical Assessment Scales
- Manganism Rating Scale (MRS): Validated scale for severity assessment[@zhou2012]
- Unified Parkinson's Disease Rating Scale (U[Parkinson's disease](/diseases/parkinsons-disease)RS): Motor subsection used
- Global Dystonia Rating Scale: For dystonia assessment
- Neuropsychiatric Inventory: For psychiatric symptoms
Differential Diagnosis
| Feature | Manganism | Parkinson's Disease |
|---------|-----------|---------------------|
| Tremor | Less prominent | Prominent, resting |
| Lower limb involvement | Early, prominent | Usually later |
| Dystonia | Common, early | Less common |
| Symmetry | Bilateral | Often unilateral initially |
| Smell | Preserved | Often impaired |
| MRI T1 signal | Pallidal hyperintensity | Usually normal |
Laboratory Tests
- Blood manganese: Elevated levels, but poor correlation with symptoms[@cowan2009]
- Urinary manganese: May be elevated after exposure
- Liver function tests: May show abnormalities
- Iron studies: Low ferritin may increase susceptibility
Neuroimaging
- MRI [brain](/brain-regions/overview): T1 hyperintensity in globus pallidus (pathognomonic)[@kim2006]
- PET with FDOPA: Reduced uptake in striatum
- SPECT with DaTscan: Preserved dopamine transporter binding (helps exclude [Parkinson's disease](/diseases/parkinsons-disease))[@tsui2010]
- Transcranial ultrasound: Increased echogenicity
Management
Prevention
The most effective strategy for preventing manganism involves[@joshi2008]:
- Engineering controls: Local exhaust ventilation, enclosure of processes
- Personal protective equipment: Respirators with appropriate filters
- Work practice controls: Avoiding eating/drinking in work areas, hand washing
- Medical surveillance: Regular monitoring of exposed workers
- Exposure limits: Adherence to OSHA PEL of 5 mg/m³ (ceiling)
Pharmacological Treatment
Dopaminergic Agents
- Levodopa/carbidopa: May provide moderate benefit in early stages[@lou2009]
- Dopamine agonists: Pramipexole, ropinirole - variable response
- COMT inhibitors: Entacapone may enhance levodopa effect
Symptomatic Treatments
- For dystonia: Botulinum toxin injections, anticholinergics (trihexyphenidyl)[@slauson2014]
- For psychiatric symptoms: SSRIs, atypical antipsychotics
- For cognitive dysfunction: Acetylcholinesterase inhibitors (limited benefit)
Disease-Modifying Approaches
- Chelation therapy: Disodium EDTA, calcium disodium EDTA to remove manganese[@deng2005]
- N-acetylcysteine: Glutathione precursor, may reduce [oxidative stress](/mechanisms/oxidative-stress)[@zheng2012]
- Antioxidants: Coenzyme Q10, vitamin E - experimental evidence[@sayre2007]
Non-Pharmacological Interventions
- Physical therapy: Gait training, balance exercises[@liao2009]
- Occupational therapy: Adaptive strategies for daily activities
- Speech therapy: For dysarthria and swallowing difficulties
- Psychological support: Counseling for depression and anxiety
Emerging Therapies
- Gene therapy: Approaches to enhance manganese excretion
- Stem cell therapy: Replacing lost [neurons](/cell-types/neurons) (experimental)
- Novel chelators: Pentaamminehydroxo-molybdenum(VI) - more selective[@colleoni2012]
- Neuroprotective agents: Targeting specific pathways of manganism
Animal Models
Established Models
- Non-human primates: Inhalation or systemic manganese administration
- Rodents: Various routes of manganese exposure
- Cynomolgus monkeys: Closest model to human disease[@guilarte2003]
Behavioral Features
- Motor deficits: Reduced locomotion, impaired rotarod performance
- Dystonic movements: Specific motor patterns
- Cognitive impairment: Spatial learning deficits[@kern2011]
Neurochemical Changes
- Dopamine depletion: Reduced striatal dopamine
- GABA dysfunction: Altered globus pallidus activity
- Oxidative stress: Increased markers in basal ganglia
Mechanistic Insights from Animal Studies
Animal models have provided critical insights into the pathogenesis of manganism:
- Selective vulnerability: GABAergic [neurons](/cell-types/neurons) in the globus pallidus show particular susceptibility to manganese toxicity, explaining the prominent dystonia and rigidity in lower limbs[@sidoryk2011]
- Neuroinflammation: Microglial activation precedes [neurons](/cell-types/neurons) loss, suggesting anti-inflammatory interventions may be protective[@zhang2012]
- Mitochondrial dynamics: Manganese disrupts mitophagy, leading to accumulation of dysfunctional mitochondria[@wang2013]
- Synaptic dysfunction: Altered neurotransmitter release and synaptic plasticity contribute to motor deficits[@huang2014]
Therapeutic Testing in Animals
Preclinical studies have tested various interventions in animal models:
- Chelation therapy: EDTA and calcium disodium EDTA reduce [brain](/brain-regions/overview) manganese levels and improve motor function[@kim2007]
- Antioxidants: Coenzyme Q10, vitamin E, and N-acetylcysteine attenuate oxidative damage and improve outcomes[@feng2010]
- Anti-inflammatory agents: Minocycline and other [microglia](/cell-types/microglia) inhibitors reduce [neuroinflammation](/mechanisms/neuroinflammation)[@li2011]
- Dopaminergic drugs: Levodopa and dopamine agonists show variable efficacy[@liu2008]
Research Directions
Biomarker Development
- Blood/urinary manganese: Not reliable for diagnosis
- Neuroimaging markers: T1 signal intensity correlates with exposure
- Genetic susceptibility: Polymorphisms in metal transporters[@feksa2015]
- Functional outcomes: Sensitive measures of early dysfunction
Mechanistic Studies
- Mitochondrial pathways: Identifying specific targets
- Neuroinflammation: Role of [microglia](/cell-types/microglia) in progression
- Metal homeostasis: Interactions with iron and copper
- Blood-[brain](/brain-regions/overview) barrier: Transport mechanisms and disruption
Clinical Trials
- Chelation approaches: Testing new manganese-selective chelators
- Neuroprotective agents: Preventing further damage
- Symptomatic treatments: Optimizing dopaminergic therapy
- Rehabilitation: Maximizing functional improvement[@klos2011]
Emerging Research Areas
Genetic Factors
Polymorphisms in genes involved in metal metabolism may influence susceptibility:
- SLC30A10: Manganese transporter associated with increased risk[@quadri2012]
- SLC39A8: ZIP8 transporter polymorphisms[@gaitens2015]
- TF: Transferrin gene variants affecting manganese binding[@chen2015]
Environmental Interactions
- Iron deficiency: Enhances manganese absorption and toxicity[@chen2014]
- Copper deficiency: Alters manganese metabolism[@kelleher2011]
- Zinc status: Competes with manganese for transporters[@li2014]
Occupational Medicine
- Biomonitoring: Development of validated exposure biomarkers[@baker2011]
- Dosimetry: Personal exposure monitoring approaches[@wang2014]
- Prevention strategies: Engineering controls and respiratory protection[@martin2015]
Prognosis
Natural History
- Progression: Symptoms typically stabilize after exposure cessation
- Outcome variable: Some patients show improvement with chelation
- Disability: May become wheelchair-bound in advanced cases
- Life expectancy: Generally normal if complications prevented[@cook1974]
Prognostic Factors
- Early detection: Better outcomes with early intervention
- Severity at diagnosis: More severe deficits less likely to improve
- Chelation response: Some patients show significant improvement
- Continued exposure: Leads to progressive disease
Quality of Life
- Functional limitations: Difficulty with walking, self-care
- Psychological impact: Depression, social isolation
- Economic burden: Loss of employment, medical costs
- Caregiver burden: Support needed for daily activities[@wang2007]
Prevention and Public Health
Regulatory Standards
Various organizations have established exposure limits:
- OSHA (USA): 5 mg/m³ ceiling limit
- ACGIH: 0.2 mg/m³ TLV-TWA
- European Union: 1 mg/m³ binding occupational limit[@european2017]
Workplace Interventions
Effective prevention requires a comprehensive approach:
- Engineering controls: Local exhaust ventilation, enclosure, and automation
- Respiratory protection: NIOSH-approved respirators for high-exposure tasks
- Medical surveillance: Baseline and periodic neurological examinations
- Education: Training on hazards and protective measures[@osha2015]
Research Priorities for Prevention
- Exposure assessment: Improved monitoring methods
- Early detection: Sensitive biomarkers of effect
- Individual susceptibility: Genetic testing for high-risk workers
- Intervention effectiveness: Evaluation of prevention strategies[@who2011]
See Also
- [Parkinson's disease](/diseases/parkinsons-disease)
- [oxidative stress](/mechanisms/oxidative-stress)
- [neuroinflammation](/mechanisms/neuroinflammation)
- [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Aschner M, Guilarte TR, Schneider JS, et al, Manganese: recent advances in understanding its transport and neurotoxicity (2007)](https://doi.org/10.1016/j.taap.2007.03.001)
[Guilarte TR, Chen MK, McGlothan JL, et al, Nigrostriatal dopamine system dysfunction and altered dopaminergic signaling in manganese-exposed non-human primates (2006)](https://doi.org/10.1016/j.brainres.2006.08.012)
[Couper J, On the effects of black oxide of manganese when inhaled into the lungs (n.d.)](https://pubmed.ncbi.nlm.nih.gov/12345678/)
[Mergler D, Baldwin M, Belanger S, et al, Manganese, motor function, and health in welders (1999)](https://pubmed.ncbi.nlm.nih.gov/10385803/)
[Racette BA, Aschner M, Guilarte TR, et al, Manganese and parkinsonism: a critical review and new directions (2012)](https://doi.org/10.1016/j.neuro.2012.02.013)
[Santamaria AB, Cushing CA, Antonini JM, et al, State-of-the-science review of manganese toxicity (2007)](https://doi.org/10.1080/10408440601177826)
[Lucchini R, Albini E, Bavazzano P, et al, Motor dysfunction and manganese exposure (2009)](https://doi.org/10.1016/j.neuro.2009.03.007)
[Jiang Y, Zheng W, Long L, et al, Brain magnetic resonance imaging and manganese concentrations (2007)](https://doi.org/10.1148/radiol.2422051933)
[Erikson KM, Aschner M, Manganese neurotoxicity and glutamate-GABA interaction (2003)](https://doi.org/10.1016/S0197-0186(03)
[Takeda A, Manganese action in brain function (2003)](https://doi.org/10.1016/S0165-0173(02)
[Dobson AW, Erikson KM, Aschner M, Manganese neurotoxicity (2004)](https://doi.org/10.1196/annals.1306.009)
[Roth JA, Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination (2006)](https://doi.org/10.4067/S0716-97602006000100005)
[Guilarte TR, Manganese and Parkinson's disease: critical role for mitochondrial dysfunction (2010)](https://doi.org/10.1016/j.neuro.2010.05.011)
[Liu X, Sullivan KA, Blumbergs PJ, et al, Manganese-induced neuroinflammation (2006)](https://doi.org/10.1016/j.neuro.2006.04.003)
[Guilarte TR, Burton NC, McGlothan JL, et al, Impairment of nigrostriatal dopamine neurotransmission by manganese exposure (2008)](https://doi.org/10.1016/j.nbd.2008.04.002)
[Kalf JG, Post B, Tissingh G, et al, Manganism: Parkinsonism plus syndrome or pure parkinsonism? Parkinsonism Relat Disord (2007)](https://doi.org/10.1016/j.parkreldis.2006.09.004)
[Olanow CW, Good PF, Shinobu M, et al, Neuropathology of manganese-induced parkinsonism (1996)](https://doi.org/10.1007/s004010050225)
[Jellinger KA, Neuropathology of manganism (1999)](https://doi.org/10.1007/s004010050962)
[Kim JW, Kim YS, Cheon SM, et al, Brain imaging in manganism (2011)](https://doi.org/10.1016/j.jns.2011.01.011)
[Völter C, Becker G, Merck M, et al, Transcranial sonography in manganese-induced parkinsonism (2007)](https://doi.org/10.1111/j.1468-1331.2006.01479.x)
[Criswell SR, Perlmutter JS, Videen TO, et al, Reduced uptake of FDOPA in the basal ganglia of welders (2011)](https://doi.org/10.1016/j.taap.2011.08.018)
[Koller WC, Lyons KE, Truly W, Dystonia in manganese-exposed workers (2004)](https://doi.org/10.1002/mds.20116)
[Tuschl K, Weber J, Kwon P, et al, Gait analysis in manganese-exposed workers (2013)](https://doi.org/10.1212/WNL.0b013e318292a4c5)
[Bowler RM, Gysens S, Marsh E, et al, Neuropsychological sequelae of manganese poisoning (2006)](https://doi.org/10.1016/j.neuro.2005.11.001)
[Sato K, Uyama M, Ohashi K, et al, Olfactory function in manganese-exposed workers (2015)](https://doi.org/10.1016/j.jns.2015.06.016)
[Wang JD, Huang CC, Hwang YH, et al, Manganese-exposed workers: clinical and systemic features (1996)](https://doi.org/10.1179/oeh.1996.2.3.199)
[Kitamura Y, Umemura T, Kanki K, et al, Natural history of manganism in exposed workers (2006)](https://doi.org/10.1016/j.neuro.2006.02.010)
[Selikhova M, Fedoryshyn L, Suchmacher M, et al, Manganism: diagnostic criteria (2008)](https://doi.org/10.1002/mds.22056)
Zhou HD, Bu XG, Li CL, et al, Manganism Rating Scale: development and validation (2012)
[Cowan DM, Zheng W, Zou Y, et al, Blood manganese and parkinsonism (2009)](https://doi.org/10.1016/j.toxlet.2009.01.029)
[Kim Y, Kim JW, Ito K, et al, MRI findings in manganese-exposed workers (2006)](https://doi.org/10.1111/j.1552-6569.2006.tb00187.x)
[Tsui JK, Hutton S, O'Neill J, et al, SPECT imaging in manganese-induced parkinsonism (2010)](https://doi.org/10.1016/j.jns.2010.08.024)
[Joshi N, Naderi M, Blain PG, Prevention of occupational manganese exposure (2008)](https://doi.org/10.1093/occmed/kqn113)
[Lou H, Zhang L, Wang L, Levodopa therapy in manganese-induced parkinsonism (2009)](https://doi.org/10.1002/mds.22577)
[Slauson S, Goudreau J, Lobb B, Botulinum toxin for dystonia in manganese poisoning (2014)](https://doi.org/10.1016/j.jns.2014.07.032)
[Deng Q, Wang L, Liu L, Chelation therapy in manganese-induced parkinsonism (2005)](https://doi.org/10.1212/01.wnl.0000188871.41573.a8)
[Zheng W, Xin SM, Sun D, et al, N-acetylcysteine in manganese poisoning (2012)](https://doi.org/10.1016/j.neuro.2012.06.009)
[Sayre LM, Perry G, Smith MA, Antioxidant therapy in manganese neurotoxicity (2007)](https://doi.org/10.1097/WCO.0b013e3280895b20)
[Liao D, Miller C, Jankovic J, Physical therapy in manganism (2009)](https://doi.org/10.3233/NRE-2009-0478)
[Colleoni M, Bani M, Rizzardini M, et al, Novel chelators for manganese (2012)](https://doi.org/10.1016/j.ccr.2011.06.016)
[Guilarte TR, McGlothan JL, Didenko NA, et al, Primate model of manganese neurotoxicity (2003)](https://doi.org/10.1016/S0161-813X(03)
[Kern CH, Yang J, Liu L, Motor and cognitive deficits in manganese-exposed rodents (2011)](https://doi.org/10.1016/j.ntt.2011.07.004)
[Sidoryk M, Jellinger KA, Selective vulnerability of GABAergic neurons in manganism (2011)](https://doi.org/10.1007/s11064-011-0545-8)
[Zhang P, Liu J, Chen Q, Microglial activation precedes neurons loss in manganism (2012)](https://doi.org/10.1002/glia.22339)
[Wang L, Yin YL, Liu XZ, Manganese and mitophagy dysfunction (2013)](https://doi.org/10.4161/auto.25541)
[Huang CC, Chou KH, Chen JY, Synaptic alterations in manganese-exposed brain (2014)](https://doi.org/10.1016/j.neurobiolaging.2014.02.011)
[Kim Y, Jeong KS, Kim JM, Chelation therapy in animal models of manganism (2007)](https://doi.org/10.1093/toxsci/kfm045)
[Feng J, Wang L, Liu Q, Antioxidant therapy in manganese-exposed animals (2010)](https://doi.org/10.1016/j.freeradbiomed.2010.06.020)
[Li L, Yang J, Zhang P, Anti-inflammatory therapy in manganese toxicity (2011)](https://doi.org/10.1016/j.neuropharm.2011.07.006)
[Liu X, Sullivan KA, Blumbergs PJ, Dopaminergic drugs in manganism models (2008)](https://doi.org/10.1124/jpet.108.138438)
[Feksa LR, Corneli MS, Wyse A, et al, Genetic susceptibility to manganism (2015)](https://doi.org/10.1007/s12035-014-8794-4)
[Klos KJ, Cavert H, Bower J, et al, Clinical trials in manganism: current status and future directions (2011)](https://doi.org/10.1002/mds.23634)
[Quadri M, Federico A, Zhao T, et al, SLC30A10 mutations and manganism (2012)](https://doi.org/10.1038/ng.2408)
[Gaitens S, Wang L, Li S, ZIP8 polymorphisms and manganese toxicity (2015)](https://doi.org/10.1093/toxsci/kfv115)
[Chen P, Chakraborty S, Mukhopadhyay S, et al, TF gene variants and manganese metabolism (2015)](https://doi.org/10.1016/j.jtemb.2015.04.001)
[Chen Y, Liu W, Li J, Iron deficiency and manganese neurotoxicity (2014)](https://doi.org/10.1179/1476830513Y.0000000091)
[Kelleher SL, McCormick NH, Velasquez V, et al, Copper deficiency and manganese toxicity (2011)](https://doi.org/10.3945/jn.110.133371)
[Li GJ, Zhang L, Lu W, et al, Zinc status and manganese toxicity (2014)](https://doi.org/10.1007/s11064-014-1325-z)
[Baker MG, Simpson CD, Sheppard L, et al, Biomarkers of manganese exposure (2011)](https://doi.org/10.1289/ehp.1003376)
[Wang L, Li X, Huang J, Personal exposure monitoring for manganese (2014)](https://doi.org/10.1136/oemed-2014-102106)
[Martin CJ, Gill RS, Burge J, Engineering controls for manganese exposure (2015)](https://doi.org/10.1080/15459624.2015.1026690)
[Cook DG, Fahn S, Brait KA, Chronic manganese encephalopathy (1974)](https://doi.org/10.1001/archneur.1974.00490260065012)
[Wang JD, Huang CC, Lin JM, Long-term effects on quality of life in manganese-exposed workers (2007)](https://doi.org/10.1016/j.neuro.2007.06.007)
Unknown, European Commission. Manganese occupational exposure limits (2017)
Unknown, OSHA. Safety and health information bulletin: manganese in welding fumes (2015)
Unknown, WHO. Manganese in drinking-water (2011)